News Details
WEB2 days ago · CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized clinical trial evaluating the efficacy, safety, and immunogenicity of an investigational norovirus vaccine, mRNA-1403. Global recruitment for the Nova 301 trial has also begun. "Norovirus is a ...
mRNA Norovirus Vaccine Candidate Launches Phase 3 Clinical Trial
WEB1 day ago · (Precision Vaccinations News) Moderna, Inc. today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized clinical trial evaluating the efficacy, safety, and immunogenicity of an investigational norovirus vaccine, mRNA-1403.
MRNA Begins Dosing in Pivotal Study on Norovirus Vaccine
WEB22 hours ago · Moderna, Inc. MRNA announced the dosing of the first participant in the phase III Nova 301 study, which is evaluating its investigational mRNA norovirus vaccine candidate, mRNA-1403, in the United ...
Moderna Announces First Participant Dosed in Pivotal Phase 3 …
WEB2 days ago · News; Stock News; Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403 ... mRNA-1403 is an mRNA vaccine in development to prevent ...
Moderna Announces First Participant Dosed in Pivotal Phase 3 …
WEB1 day ago · CAMBRIDGE - Moderna, Inc. (NASDAQ: MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized clinical trial evaluating the efficacy, safety, and immunogenicity of an investigational norovirus vaccine, mRNA-1403. Global recruitment for the Nova 301 trial has also begun. 'Norovirus is a significant public health concern that ...
News Details
WEBMar 27, 2024 · An interim analysis showed that a single dose of mRNA-1403 elicited a robust immune response across all dose levels evaluated with a clinically acceptable reactogenicity and safety profile. The Company is advancing mRNA …
Moderna R&D Day Highlights Progress and Strategic Priorities
WEBSep 12, 2024 · An interim analysis showed that a single dose of mRNA-1403 elicited a robust immune response across all dose levels evaluated with a clinically acceptable reactogenicity and safety profile.
Moderna doses first subject in Phase III trial of mRNA norovirus
WEBU S-based pharmaceutical company Moderna has dosed the first subject in the US in its Phase III Nova 301 clinical trial of its investigational norovirus vaccine, mRNA-1403. The Nova 301 trial aims ...
Moderna touts 3 phase 1 data sets to bolster early vax work
WEBMar 27, 2024 · Moderna’s presentation centered on one of the two, MRNA-1403, finding that the vaccine elicited a stronger immune response than placebo against two common norovirus genotypes.
MRNA-1403 by Moderna for Norovirus Infections: Likelihood of …
WEBAug 28, 2024 · mRNA-1403 is under development for prevention of acute gastroenteritis caused by norovirus in young children and older adults. The vaccine candidate is a trivalent norovirus vaccine comprising mRNA expressing virus-like particles (VLPs).
- Some results have been removed